Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > tarceva

Tarceva (OSI-774 or erlotinib) : OSI Pharmaceuticals/Genentech : EGFR inhibitor

FDA Approves Tarceva for Lung Cancer: Drug Shows Survival Benefit (FDA)
FDA announces approval of Tarceva (erlotinib) as a single agent treatment for patients with locally advanced or metastatic NSCLC whose cancer has continued to progress despite other treatments. Tarceva has been shown to improve survival in a randomized trial comparing Tarceva to placebo. [11/04]

Tarceva for NSCLC (National Cancer Institute)
Discusses the basis for FDA approval of Tarceva as a treatment for lung cancer patients with locally advanced or metastatic NSCLC after at least one prior chemotherapy regimen. [11/04]

Tarceva (Erlotinib) Extends Survival in Advanced Lung Cancer (National Cancer Institute)
Discusses the results of a controlled Phase III study of Tarceva (erlotinib), a targeted drug that inhibits the epidermal growth factor receptor (EGFR). The study showed improved survival in previously treated patients with NSCLC - patients receiving Tarceva lived longer than those in the placebo arm of the study. The trial also demonstrated that Tarceva improved: 1) time to symptomatic deterioration; 2) progression-free survival and response rate. [6/04]

New Drug Shows Promise in Treating Patients with BAC (People Living With Cancer)
Reports on a Phase II study presented at the 2003 ASCO annual meeting that found the targeted drug erlotinib (Tarceva) showed encouraging results in patients with BAC. In 30 patients with BAC who had been treated with erlotinib for one month or more, eight (27%) responded to the drug. Researchers also found that erlotinib was more effective in patients who had never smoked. [5/03]

Tarceva (OSI Pharmaceuticals/Genentech)
Manufacturer's website provides comprehensive information on Tarceva, including product, safety, insurance, and clinical trials information.

Tarceva & Lung Cancer - Recent MEDLINE Abstracts

Tarceva - Clinical Trials (


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor